Lytix Biopharma AS Cash Flow Statement

Financials in millions NOK. Fiscal year is January - December.

Millions NOK. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2017 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2017 - 2019
Net Income	-94.27	-87.9	-56.07	-48.08	-42.09	Upgrade
Depreciation & Amortization	0.92	0.96	0.92	0.45	-	Upgrade
Stock-Based Compensation	0.88	4.18	1.38	4.05	8.4	Upgrade
Other Operating Activities	-1.5	-2.35	-1.35	-0.13	-0	Upgrade
Change in Accounts Receivable	-0.34	-6.04	-1.06	-1.51	0.47	Upgrade
Change in Accounts Payable	23.94	-4.83	3.55	0.61	8.87	Upgrade
Operating Cash Flow	-70.37	-95.97	-52.63	-44.61	-24.35	Upgrade
Capital Expenditures	-	-0.05	-0.15	-	-	Upgrade
Investment in Securities	23.18	27.42	-50.61	-	-	Upgrade
Other Investing Activities	1.51	2.35	1.41	0.14	-	Upgrade
Investing Cash Flow	24.69	29.73	-49.36	0.14	-	Upgrade
Long-Term Debt Repaid	-0.85	-0.94	-0.83	-0.42	-	Upgrade
Net Debt Issued (Repaid)	-0.85	-0.94	-0.83	-0.42	-	Upgrade
Issuance of Common Stock	161.3	-	0.13	225.21	40	Upgrade
Other Financing Activities	-11.34	-0	-0.06	-11.49	-	Upgrade
Financing Cash Flow	149.11	-0.94	-0.75	213.3	40	Upgrade
Miscellaneous Cash Flow Adjustments	-	-	-	-0	-	Upgrade
Net Cash Flow	103.43	-67.19	-102.73	168.83	15.65	Upgrade
Free Cash Flow	-70.37	-96.02	-52.78	-44.61	-24.35	Upgrade
Free Cash Flow Margin	-632.05%	-2405.86%	-478.47%	-231.04%	-597.62%	Upgrade
Free Cash Flow Per Share	-1.30	-2.40	-1.33	-1.34	-0.93	Upgrade
Cash Interest Paid	0.01	0	0.06	0	-	Upgrade
Levered Free Cash Flow	-34.62	-66.3	-36.49	-26.43	-8.74	Upgrade
Unlevered Free Cash Flow	-34.54	-66.27	-36.4	-26.39	-8.74	Upgrade
Change in Net Working Capital	-23.6	10.87	-2.5	0.9	-9.35	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.